Related Experiment Video
Updated: Aug 20, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
Epigenetic inactivation of COL4A4 orchestrates JAK2/STAT3-driven progression and microenvironment reprogramming in
Hanxi Zhou1, Xiong Tian1, Zhenyu Yang1
1Department of Public Research Platform, Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai 317000, China.
Background:
Renal cell carcinoma (RCC) is a common urinary malignancy that lacks reliable early biomarkers. Although epigenetic silencing of tumor suppressor genes mediated by DNA methylation is common in RCC, the specific role and regulation of the basement membrane component COL4A4 remain unclear.
Methods:
Bulk and single-cell RNA sequencing (scRNA-seq), DNA methylation analysis, The Cancer Genome Atlas data and in-house clinical RCC cohorts were integrated to characterize COL4A4 expression, epigenetic regulation, clinical significance, and associations with tumor microenvironment (TME) features. The biological functions of COL4A4 were evaluated using in vitro functional assays and in vivo xenograft models. Mechanistic studies included 5-Aza demethylation treatment and JAK2/STAT3 pathway inhibition.
Results:
COL4A4 was downregulated in RCC, and its downregulation is associated with promoter hypermethylation, serving as an independent prognostic factor. Functionally, COL4A4 inhibited RCC cell proliferation, migration, and invasion in vitro, and suppressed tumor growth in vivo. Mechanistically, COL4A4 negatively modulated the JAK2/STAT3 signaling pathway. scRNA-seq revealed that COL4A4 was predominantly enriched in epithelial cells. Low COL4A4 expression is associated with altered extracellular matrix-receptor interactions and an immunosuppressive TME.
Conclusions:
COL4A4 acts as a methylation-silenced RCC tumor suppressor that negatively modulates JAK2/STAT3 signaling and correlates with TME features, representing a potential epigenetic therapeutic target.
Insights
Collagen type IV alpha 4 (COL4A4) acts as a tumor suppressor in renal cell carcinoma (RCC). Its downregulation, due to DNA methylation, impacts the tumor microenvironment and offers a potential epigenetic therapeutic target for RCC.
Area of Science:
- Oncology
- Epigenetics
- Molecular Biology
Background:
- Renal cell carcinoma (RCC) lacks effective early detection biomarkers.
- Epigenetic silencing via DNA methylation is prevalent in RCC.
- The role of COL4A4 in RCC pathogenesis and its regulation are not well understood.
Purpose of the Study:
- To investigate the expression, epigenetic regulation, and clinical significance of COL4A4 in RCC.
- To elucidate the functional role of COL4A4 in RCC progression and its association with the tumor microenvironment (TME).
- To explore COL4A4 as a potential therapeutic target in RCC.
Main Methods:
- Integrated analysis of bulk and single-cell RNA sequencing (scRNA-seq), DNA methylation data, and clinical cohorts.
- In vitro functional assays and in vivo xenograft models to assess COL4A4's biological functions.
- Mechanistic studies involving demethylation treatment and pathway inhibition (JAK2/STAT3).
Main Results:
- COL4A4 expression is downregulated in RCC, linked to promoter hypermethylation, and serves as an independent prognostic factor.
- COL4A4 suppresses RCC cell proliferation, migration, invasion, and tumor growth by negatively modulating the JAK2/STAT3 pathway.
- Low COL4A4 expression correlates with altered extracellular matrix-receptor interactions and an immunosuppressive TME.
Conclusions:
- COL4A4 functions as a methylation-silenced tumor suppressor in RCC.
- COL4A4 negatively regulates JAK2/STAT3 signaling and influences TME characteristics.
- COL4A4 represents a promising epigenetic therapeutic target for renal cell carcinoma.
Related Concept Videos
The JAK-STAT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
The Tumor Microenvironment
